NEWS: 公告在東京證券交易所JASDAQ標準市場新上市

表紙
市場調查報告書

切片設備市場 - 預測(2021年∼2026年)

Biopsy Devices Market - Forecasts from 2021 to 2026

出版商 Knowledge Sourcing Intelligence 商品編碼 1023168
出版日期 內容資訊 英文 115 Pages
商品交期: 最快1-2個工作天內
價格
切片設備市場 - 預測(2021年∼2026年) Biopsy Devices Market - Forecasts from 2021 to 2026
出版日期: 2021年07月05日內容資訊: 英文 115 Pages
簡介

全球切片設備的市場規模,預計從2019年的17億2,200萬美元到2026年達到27億2,400萬美元,在預期期間中以6.77%的年複合成長率成長。

推動市場成長的主要原因之一是慢性疾病的發病率不斷上升,尤其是乳腺癌。此外,隨著消費者對慢性病診斷和篩查方法可用性的了解不斷增加,對立體定向引導切片等整合技術的需求也成長。世界各地的患者日益選擇微創切片治療。各種技術進步,包括導入真空輔助槍和有助於區分健康細胞和腫瘤細胞的智慧切片系統,也有助於推動市場擴張。預計未來幾年推動市場發展的其他因素包括老年人口擴大,醫療保健支出不斷增加以及大量的研發工作。

本報告提供切片設備的世界市場調查,市場概要,市場阻礙因素,競爭情形,產品的各類型、各應用領域、各地區等的市場分析,並提供主要企業簡介等資料。

目錄

第1章 簡介

  • 市場定義
  • 市場區隔

第2章 調查手法

  • 調查資料
  • 前提條件

第3章 摘要整理

  • 調查的重點

第4章 市場動態

  • 市場推動因素
  • 市場阻礙因素
  • 波特的五力分析
    • 終端用戶的交易
    • 購買企業的交易
    • 新加入業者的威脅
    • 替代品的威脅
    • 產業的競爭企業間的競爭關係
  • 產業的價值鏈分析

第5章 各產品類型:切片設備的市場分析

  • 簡介
  • 針為基礎的切片檢查器具
  • 切片檢查套組
  • 導管導引線
  • 其他

第6章 各應用領域:切片設備的市場分析

  • 簡介
  • 肺切片檢查
  • 前列腺切片檢查
  • 結腸直腸切片檢查
  • 乳房切片
  • 其他

第7章 各終端用戶:切片設備的市場分析

  • 簡介
  • 醫院
  • 診斷及影像中心
  • 學術、調查機關

第8章 各地區:切片設備的市場分析

  • 簡介
  • 北美
    • 美國
    • 加拿大
    • 墨西哥
  • 南美
    • 巴西
    • 阿根廷
    • 其他
  • 歐洲
    • 德國
    • 法國
    • 英國
    • 其他
  • 中東和非洲
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 其他
  • 亞太地區
    • 中國
    • 印度
    • 日本
    • 韓國
    • 台灣
    • 泰國
    • 印尼
    • 其他

第9章 競爭環境與分析

  • 主要企業策略分析
  • 新興企業和市場收益性
  • 合併,收購,協定,及共同研究
  • 供應商競爭力 矩陣

第10章 企業簡介

  • Becton, Dickinson and Company
  • Argon Medical Devices, Inc.
  • C. R. Bard, Inc.
  • Cardinal Health, Inc.
  • Devicor Medical Products, Inc.(Mammotome)
  • B. Braun Melsungen AG
  • Olympus Corporation
  • Fujifilm Holdings Corporation
  • Inrad, Inc.
  • Cook Group Incorporated
  • Boston Scientific Corporation
目錄
Product Code: KSI061611761

The biopsy devices market is projected to grow at a CAGR of 6.77% during the forecast period to reach a market size of US$2.724 billion in 2026 from US$1.722 billion in 2019. Biopsy devices are numerous types of equipment used in the surgical removal of tissues from an organ. Surgeons, radiologists, cardiologists, and other medical professionals use them to determine the existence and degree of malignant and inflammatory illnesses. Some of the most often used biopsy instruments are aspiration needles, forceps, and localization wires. These instruments are utilized in MRI-guided, needle-based, core, and vacuum-assisted biopsies of the liver, lungs, kidneys, and breasts, among other body regions. They're used in a wide range of healthcare settings, including medical clinics, diagnostic centers, and hospitals.

One of the primary reasons driving the market's growth is the growing incidence of chronic medical conditions, particularly breast cancer. Furthermore, as consumer knowledge of the availability of diagnostic and screening methods for chronic illnesses grows, demand for integrated technologies like stereotactic-guided biopsies grows. Patients all across the world are increasingly opting for minimally invasive biopsy treatments. Various technical advances, including the introduction of vacuum-assisted guns and smart biopsy systems that aid in the differentiation of healthy cells from tumorous cells, are also helping to drive market expansion. Other factors anticipated to propel the market in the future years include the constantly expanding geriatric population, rising healthcare expenditures, and substantial research and development efforts.

Biopsy is one of the most common methods for diagnosing cancer diseases, and it is commonly employed in the diagnosis of breast, skin, and prostate cancer. The International Agency for Research on Cancer estimates that there were nearly 19.3 million new cancer cases in 2020, globally. The increasing number of cancer cases is one of the major drivers of the market.

The market is seeing a substantial increase in demand for minimally invasive biopsy treatments.

Various technologies and products, including biopsy guidance systems, needle-based biopsy guns, and vacuum-assisted devices, are expected to expand rapidly throughout the projected period.

For soft tissue biopsies, Izi Medical Products introduced the Quick-Core Auto Biopsy System in March 2021. The Quick-Core Auto is a small, completely automated biopsy equipment that improves on the company's prior semi-automatic method. For tissue samples, Izi's Quick-Core Auto offers three programmed firing modes: automatic, delay, and zero-throw.

Hologic, Inc., a medical technology business focused on improving women's health, in January 2021, completed the $64 million purchase of SOMATEX Medical Solutions GmbH, a pioneer in biopsy site markers and localization technologies. Hologic will also strengthen its sales presence in Europe as a result of the purchase, by extending its direct channel in Germany as well as its network of regional and worldwide distributor partners.

Furthermore, rising awareness of breast cancer treatment and diagnosis will promote growth in the market size for biopsy equipment in the future years. Many nations have programs to detect breast cancer in its early stages. As a result, such measures will hasten the adoption of biopsy instruments, resulting in a favorable influence on growth. For instance, the US Centers for Disease Control and Prevention, Division of Cancer Prevention and Control, through its three national public health campaigns namely Screen for Life: National Colorectal Cancer Action Campaign, Inside Knowledge About Gynecologic Cancer Campaign, and Bring your Brave, educates people about the symptoms of cancer and how to reduce your risk.

The increasing geriatric population is further expected to complement the market growth.

As reported by US National Cancer Institute, the most major risk factor for cancer in general, as well as for many specific cancer types, is growing older. Overall, cancer incidence rates rise gradually with age, from fewer than 25 cases per 100,000 people in age groups under 20 to around 350 cases per 100,000 people in age groups 45-49, and more than 1,000 cases per 100,000 people in age groups 60 and beyond. Breast cancer is diagnosed at a median age of 62 years, colorectal cancer at 67 years, lung cancer at 71 years, and prostate cancer at 66 years.

Geographically, North America was the market's largest revenue generator.

North America will continue to account for a significant part of the market during the projection period owing to established industry players based in the region. The regional market is projected to benefit from high market penetration rates of technologically sophisticated devices such as vacuum-assisted biopsy systems and skyrocketing demand for disposable devices. There are several government-sponsored health initiatives focused on encouraging people to get frequent cancer screenings. The Aisa Pacific market is expected to develop due to rapidly improving healthcare infrastructure in the emerging nations, as well as the prevalence of significant unmet patient requirements and a rising occurrence of cancer.

Market Segmentation:

  • By Product Type

Needle-based Biopsy Instruments

Procedure Trays

Localization Wires

Others

  • By Application

Lung Biopsy

Prostate Biopsy

Colorectal Biopsy

Breast Biopsy

Others

  • By End-User

Hospitals

Diagnostic and Imaging Centers

Academic & Research Institutes

  • By Geography

North America

  • USA
  • Canada
  • Mexico

South America

  • Brazil
  • Argentina
  • Others

Europe

  • UK
  • Germany
  • France
  • Spain
  • Others

Middle East and Africa

  • Saudi Arabia
  • UAE
  • Israel
  • Others

Asia Pacific

  • Japan
  • China
  • India
  • South Korea
  • Taiwan
  • Thailand
  • Indonesia
  • Others

Table of Contents

1. Introduction

  • 1.1. Market Definition
  • 1.2. Market Segmentation

2. Research Methodology

  • 2.1. Research Data
  • 2.2. Assumptions

3. Executive Summary

  • 3.1. Research Highlights

4. Market Dynamics

  • 4.1. Market Drivers
  • 4.2. Market Restraints
  • 4.3. Porters Five Forces Analysis
    • 4.3.1. Bargaining Power of End-Users
    • 4.3.2. Bargaining Power of Buyers
    • 4.3.3. Threat of New Entrants
    • 4.3.4. Threat of Substitutes
    • 4.3.5. Competitive Rivalry in the Industry
  • 4.4. Industry Value Chain Analysis

5. Biopsy Devices Market Analysis, by Product Type

  • 5.1. Introduction
  • 5.2. Needle-based Biopsy Instruments
  • 5.3. Procedure Trays
  • 5.4. Localization Wires
  • 5.5. Others

6. Biopsy Devices Market Analysis, by Application

  • 6.1. Introduction
  • 6.2. Lung Biopsy
  • 6.3. Prostate Biopsy
  • 6.4. Colorectal Biopsy
  • 6.5. Breast Biopsy
  • 6.6. Others

7. Biopsy Devices Market Analysis, by End-User

  • 7.1. Introduction
  • 7.2. Hospitals
  • 7.3. Diagnostic and Imaging Centers
  • 7.4. Academic & Research Institutes

8. Biopsy Devices Market Analysis, by Geography

  • 8.1. Introduction
  • 8.2. North America
    • 8.2.1. USA
    • 8.2.2. Canada
    • 8.2.3. Mexico
  • 8.3. South America
    • 8.3.1. Brazil
    • 8.3.2. Argentina
    • 8.3.3. Others
  • 8.4. Europe
    • 8.4.1. Germany
    • 8.4.2. France
    • 8.4.3. UK
    • 8.4.4. Others
  • 8.5. Middle East and Africa
    • 8.5.1. Saudi Arabia
    • 8.5.2. UAE
    • 8.5.3. Others
  • 8.6. Asia Pacific
    • 8.6.1. China
    • 8.6.2. India
    • 8.6.3. Japan
    • 8.6.4. South Korea
    • 8.6.5. Taiwan
    • 8.6.6. Thailand
    • 8.6.7. Indonesia
    • 8.6.8. Others

9. Competitive Environment and Analysis

  • 9.1. Major Players and Strategy Analysis
  • 9.2. Emerging Players and Market Lucrativeness
  • 9.3. Mergers, Acquisitions, Agreements, and Collaborations
  • 9.4. Vendor Competitiveness Matrix

10. Company Profiles

  • 10.1. Becton, Dickinson and Company
  • 10.2. Argon Medical Devices, Inc.
  • 10.3. C. R. Bard, Inc.
  • 10.4. Cardinal Health, Inc.
  • 10.5. Devicor Medical Products, Inc. (Mammotome)
  • 10.6. B. Braun Melsungen AG
  • 10.7. Olympus Corporation
  • 10.8. Fujifilm Holdings Corporation
  • 10.9. Inrad, Inc.
  • 10.10. Cook Group Incorporated
  • 10.11. Boston Scientific Corporation